Scios Natrecor Physician Education Should Address Hypotension Risk
Executive Summary
Scios' Natrecor physician education program should highlight the potential for symptomatic hypotension with the decompensated congestive heart failure treatment, FDA's Cardiovascular & Renal Drugs Advisory Committee said May 25.
You may also be interested in...
Scios To Launch Heart Failure Registry Simultaneous With Natrecor Marketing
Scios will initiate a congestive heart failure patient registry in conjunction with the launch of Natrecor (nesiritide) for treatment of acute decompensated CHF, CEO Richard Brewer said July 10.
Scios To Launch Heart Failure Registry Simultaneous With Natrecor Marketing
Scios will initiate a congestive heart failure patient registry in conjunction with the launch of Natrecor (nesiritide) for treatment of acute decompensated CHF, CEO Richard Brewer said July 10.
Scios Natrecor Pharmacoeconomic Study To Address Length Of Stay Concerns
Scios Natrecor pharmacoeconomic study will address advisory committee concern about a one-day longer hospital stay for Natrecor than for nitroglycerin, CEO Richard Brewer told analysts following the committee meeting May 25.